The Claim
Dietary rapamycin administered to genetically heterogeneous mice beginning at 600 days of age (equivalent to approximately 60 years in humans) is associated with increased median lifespan in both male and female mice, with effect sizes of 13% and 9% respectively in pooled analysis across three test sites.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Giving old mice rapamycin in their food when they're about 60 in human years helps them live longer - males lived 13% longer and females 9% longer on average.
See the scientific wording
Dietary rapamycin administered to genetically heterogeneous mice beginning at 600 days of age (equivalent to approximately 60 years in humans) is associated with increased median lifespan in both male and female mice, with effect sizes of 13% and 9% respectively in pooled analysis across three test sites.
What the research says
1 studyStudy: Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
The study gave rapamycin to mice starting at 600 days old (like starting treatment at age 60 in humans) and found that both male and female mice lived longer. The effect was seen at three different labs, confirming the results are reliable. This directly supports the claim that late-life rapamycin extends lifespan in mice.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.